ArticleDrug delivery and translational research2011
Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy.
Article in Drug delivery and translational research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Application of Biocompatible Drug Delivery Nanosystems for the Treatment of Naturally Occurring Cancer in Dogs.Journal of functional biomaterials · 2022Review
- Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer.Drug delivery and translational research · 2021Article
- Recent Advances of Taxol-Loaded Biocompatible Nanocarriers Embedded in Natural Polymer-Based Hydrogels.Gels (Basel, Switzerland) · 2021Review
- Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases.Drug delivery and translational research · 2020Review
- Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.3 Biotech · 2020Review
- Antitumor Features of Vegetal Protein-Based Nanotherapeutics.Pharmaceutics · 2020Review
- Paclitaxel-loaded sodium deoxycholate-stabilized zein nanoparticles: characterization andHeliyon · 2019Article
- Cytotoxic Effect of Paclitaxel and LapatinibPharmaceutics · 2019Article
- Drug-Loaded Biocompatible Nanocarriers Embedded in Poloxamer 407 Hydrogels as Therapeutic Formulations.Medicines (Basel, Switzerland) · 2018Review
- Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview.Materials (Basel, Switzerland) · 2018Review
- Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.AAPS PharmSciTech · 2018Article
- Application of Light Scattering Techniques to Nanoparticle Characterization and Development.Frontiers in chemistry · 2018Review
- PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity.Nanomaterials (Basel, Switzerland) · 2016Article
- Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.Drug delivery and translational research · 2015Article
- Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes.International journal of nanomedicine · 2015Article
- Multicompartimental nanoparticles for co-encapsulation and multimodal drug delivery to tumor cells and neovasculature.Pharmaceutical research · 2014Article
- Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.International journal of nanomedicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new PEGylated liposomal formulation containing both gemcitabine (GEM) and paclitaxel (PTX) was investigated in order to realize an innovative multidrug carrier (MDC) to test on human cancer cells. The MDC in question was realized by the liposome extrusion method. Photocorrelation spectroscopy was used for the physicochemical characterization of the vesicular carriers. In vitro cytotoxicity was studied through MTT testing. The contemporary presence of the two antitumoral compounds induced no destabilization phenomena in the liposomal structure. The extrusion method provided vesicles with mean sizes of ∼100 nm and a zeta-potential of ∼ -10 mV. The liposomal MDC showed a high drug loading capacity (∼90% and ∼80% for GEM and PTX, respectively) as well as a controlled release of the active compounds over a 24-h period. Cell viability testing on Michigan Cancer Foundation-7 human breast cancer cells evidenced the MDC as having a stronger cytotoxic effect with respect to the active compounds tested in free and liposomal formulations, both as single molecules and in association. Flow cytometry furnished evidence of the synergistic in vitro antitumoral action between the GEM and PTX co-encapsulated the liposomal MDC. This formulation may offer even more advantages in in vivo testing in terms of drug pharmacokinetic, biodistribution, and antitumoral efficacy for the treatment of breast cancer, as compared to past formulations.
Identifiers
25787890What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.